Cambridge genomics research foundation translating molecular cancer science into precision health policy and healthcare system implementation across Europe.
The Foundation for Genomics & Population Health is a Cambridge-based research organisation that translates advances in genomics into public health and clinical practice. Their work spans two linked domains: the molecular science of disease risk (identifying germline variants, tumour subtypes, and lifestyle risk factors in cancer) and the systemic challenge of integrating genomic medicine into healthcare systems at scale. In B-CAST they contributed to stratifying breast cancer patients by molecular and epidemiological profiles to improve prognosis and personalise care. In ExACT they shifted upstream to address how precision health concepts—including big data, health technology assessment, and ethical frameworks—can be embedded into European healthcare systems through professional education and citizen engagement.
B-CAST (2015–2021) involved characterising breast cancer molecular subtypes, germline susceptibility variants, tumour sequencing, and breast density to improve risk prediction and prognosis.
ExACT (2019–2024) focused on embedding precision health into European healthcare systems through staff exchange, professional education, and leadership development.
ExACT explicitly listed health technology assessment and ethics as core themes, reflecting the foundation's role in evaluating real-world clinical and societal implications of genomic approaches.
Citizen engagement appears as a keyword in ExACT, suggesting growing activity in public-facing health literacy and participatory approaches to precision medicine adoption.
In their first H2020 project (starting 2015), the foundation was embedded in disease-specific molecular research: germline variants, tumour sequencing, breast density, and cancer subtyping — work close to the laboratory and clinical data end of the research spectrum. By 2019, their focus had shifted markedly toward the systems and governance layer: how precision health gets implemented in practice, who makes those decisions, what ethical constraints apply, and how healthcare professionals are trained to deliver it. This progression — from molecular mechanisms to systemic implementation — suggests the organisation is positioning itself as a translator between genomic science and health policy rather than a producer of primary molecular data.
They are moving toward the science-policy interface — future collaborations will likely involve them as the bridge between what genomics can do and what healthcare systems are ready to adopt, particularly on HTA, ethics, and professional education.
The foundation has participated only as a partner in both H2020 projects, never as coordinator, which signals they function as a specialist contributor rather than a consortium driver. Despite that, they have engaged with 29 distinct partners across 13 countries from just two projects — indicating participation in large, multi-institutional European consortia where they bring focused domain expertise. Organisations considering working with them should expect a reliable, engaged partner with deep thematic input rather than administrative leadership.
With 29 unique consortium partners across 13 countries from only two projects, the foundation consistently joins large pan-European research networks. There is no visible geographic concentration, pointing to a broad European reach in the health and genomics research community.
Few organisations combine hands-on cancer genomics expertise with active engagement in health technology assessment, ethics, and system-level implementation — most sit firmly on one side of that divide. Based in Cambridge, the foundation operates at a recognised European hub for genomics and population health, giving it strong academic credibility alongside policy relevance. For consortium builders, they fill the often-missing role of the partner who can both read the science and translate it into what health systems actually need to hear.
